USE OF NON-FEMINIZING ESTROGENS AS RETINOPROTECTIVE AGENTS FOR THE TREATMENT OF GLAUCOMA
    1.
    发明申请
    USE OF NON-FEMINIZING ESTROGENS AS RETINOPROTECTIVE AGENTS FOR THE TREATMENT OF GLAUCOMA 失效
    使用非有限化雌激素作为治疗GLAUCOMA的转基因保护剂

    公开(公告)号:US20070225263A1

    公开(公告)日:2007-09-27

    申请号:US11754710

    申请日:2007-05-29

    IPC分类号: A61K31/56

    CPC分类号: A61K31/56

    摘要: The invention provides pharmaceutical compositions containing non-feminizing estrogen and methods of using these compositions to prevent or ameliorate retinal and optic nerve damage associated with glaucoma.

    摘要翻译: 本发明提供含有非女性化雌激素的药物组合物和使用这些组合物以预防或改善与青光眼相关的视网膜和视神经损伤的方法。

    RNAi-mediated inhibition of RHO kinase for treatment of ocular disorders
    3.
    发明申请
    RNAi-mediated inhibition of RHO kinase for treatment of ocular disorders 审中-公开
    RNAi介导的RHO激酶抑制治疗眼部疾病

    公开(公告)号:US20070149473A1

    公开(公告)日:2007-06-28

    申请号:US11641410

    申请日:2006-12-19

    IPC分类号: A61K48/00

    摘要: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.

    摘要翻译: 提供了用于抑制Rho激酶mRNA表达以治疗眼部疾病患者的RNA干扰,特别是用于治疗眼内压,眼高压和青光眼。 Rho激酶mRNA靶标包括ROCK1和ROCK2的mRNA。

    PAI-1 BINDING MODULATORS FOR THE TREATMENT OF OCULAR DISORDERS
    5.
    发明申请
    PAI-1 BINDING MODULATORS FOR THE TREATMENT OF OCULAR DISORDERS 审中-公开
    用于治疗眼病的PAI-1结合调节剂

    公开(公告)号:US20080107644A1

    公开(公告)日:2008-05-08

    申请号:US11931393

    申请日:2007-10-31

    IPC分类号: A61K39/395 A61P27/06

    摘要: The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that modulates PAI-1 binding to vitronectin. In another embodiment, the invention concerns a method of manufacturing a compound to be used as a treatment for glaucoma or elevated IOP comprising providing a candidate substance suspected of modulating PAI-1 binding, selecting the compound by assessing the ability of the candidate substance to decrease the amount of active PAI-1 in the trabecular meshwork of a subject suffering from glaucoma or elevated PAI-1, and manufacturing the selected compound.

    摘要翻译: 本发明在一个实施方案中涉及用于治疗患者青光眼或升高的IOP的方法,包括向患者施用有效量的包含调节PAI-1与玻连蛋白结合的试剂的组合物。 在另一个实施方案中,本发明涉及制备待用作青光眼或升高的IOP治疗的化合物的方法,包括提供疑似调节PAI-1结合的候选物质,通过评估候选物质降低的能力来选择该化合物 在患有青光眼或升高的PAI-1的受试者的小梁网中活性PAI-1的量,并制备所选择的化合物。